ALVEOLAR RHABDOMYOSARCOMA TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Moreover, various government and non-government organizations are undertaking research initiatives to improve the outcomes of alveolar rhabdomyosarcoma as the condition is associated with lower survival rates. Several clinical trials are conducted by large international cooperative groups, such as Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) and the National Comprehensive Cancer Network (NCCN) to provide innovative treatments based on latest research, which in turn is expected to bolster market growth in the forecast period. Also, researchers at Oregon Health & Science University Doernbecher Children's Hospital have identified a promising new approach to overcoming drug resistance and increase the survival rate in children with alveolar rhabdomyosarcoma. According to the Oregaon Health and Science University, 2011, the survival rate among alveolar rhabdomyosarcoma patients after extensive therapy is less than 20%.